Recent evidence has directly linked integrin expression to EGFR TKI resistance in NSCLC cell lines with reduced phosphorylation of ERK and Akt contributing to increased sensitivity to gefitinib in cell lines depleted of β1 integrin [28]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.